Percutaneous Transluminal Stenting for Superior Vena Cava Syndrome Caused by Malignant Tumors : A Single Center Retrospective Study

• Published in: Journal of Cardiothoracic Surgery
• Main Authors: Liu, Haitao, Li, Yahua, Wang, Yang, Yan, Lei, Zhou, Pengli, Han, Xinwei
• Format: Web Resource
• Language: English
• Published: Durham Research Square 26.10.2020
• Subjects: Patients; Stents; Tumors
• DOI: 10.21203/rs.3.rs-96027/v1

Objectives：To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors. Methods：To retrospectively analyze the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatment in our department from 2015 to 2019 due to malignant tumors, and summarize the patient’s gender, age, tumor type, endovascular treatment plan, complications and postoperative follow-up. Results：All patients successfully underwent percutaneous intraluminal stent placement with digital subtraction angiography (DSA). Thirty seven endovascular stents were implanted in 32 patients, including 21 Eluminexx stents, 12 Wallstent stents, and 4 covered stents..The technical success rate was 100%, and there were no serious surgery-related complications.The remission rate of clinical symptoms was 53.1% (17 / 32) in 24 hours and 84.4% (27 / 32) in 48 hours. The follow-up period was 1.5-24 months, with an average follow-up period of 6.5 months. During the follow-up, 3 patients had re-stenosis and 1 patient had secondary thrombosis in the stent. The symptoms were relieved after the second treatment. Conclusion: For superior vena cava syndrome caused by malignant tumors, percutaneous endoluminal stent therapy can quickly and effectively relieve the clinical symptoms of patients, and the incidence of complications is low. It should be used as a first-line treatment.